公开(公告)号：US12070500B2

公开(公告)日：2024-08-27

申请号：US17362020

申请日：2021-06-29

Applicant: Vaccinex, Inc.

Inventor： Elizabeth E. Evans ,  Ernest S. Smith ,  Maurice Zauderer

IPC: A61K39/395 ,  A61P35/00 ,  A61P37/04 ,  A61K31/675 ,  A61K35/15 ,  A61K38/20 ,  A61K39/00 ,  C07K14/47 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C12N5/0783 ,  G01N33/50

CPC classification number: A61K39/39558 ,  A61K39/3955 ,  A61P35/00 ,  A61P37/04 ,  A61K31/675 ,  A61K35/15 ,  A61K38/2013 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/572 ,  C07K14/4705 ,  C07K14/70596 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/73 ,  C07K2317/76 ,  C12N5/0638 ,  C12N2501/2302 ,  C12N2501/998 ,  G01N33/5094

Abstract: Provided herein are methods for inhibiting, delaying, or reducing tumor growth and metastases of Plexin-B1-expressing cancer cells in a subject, comprising administering to the subject an effective amount of an isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) in combination with an effective amount of at least one other immune modulating therapy.

公开(公告)号：US20240279354A1

公开(公告)日：2024-08-22

申请号：US18626607

申请日：2024-04-04

Applicant: AMUNIX PHARMACEUTICALS, INC.

Inventor： Volker SCHELLENBERGER ,  Fan YANG ,  Desiree THAYER ,  Bee-Cheng SIM ,  Chia-Wei WANG

IPC: C07K16/30 ,  A61K38/00 ,  A61K39/00 ,  A61P35/00 ,  C07K14/00 ,  C07K16/28 ,  C12N5/09

CPC classification number: C07K16/30 ,  A61P35/00 ,  C07K14/00 ,  C07K16/2809 ,  C12N5/0693 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/572 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/60 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/90 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/01 ,  C07K2319/035 ,  C07K2319/21 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/50 ,  C12N2523/00

Abstract: The present invention relates to bispecific chimeric polypeptide assembly compositions comprising bulking moieties linked to binding domains by cleavable release segments that, when cleaved are capable of concurrently binding effector T cells with targeted tumor or cancer cells and effecting cytolysis of the tumor cells or cancer cells. The invention also provides compositions and methods of making and using the cleavable chimeric polypeptide assembly compositions.

公开(公告)号：US12065506B2

公开(公告)日：2024-08-20

申请号：US18159827

申请日：2023-01-26

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Lisa A. Purcell

IPC: C07K16/10 ,  A61K9/00 ,  A61K39/395 ,  A61K39/42 ,  A61P31/16 ,  C07K14/005 ,  C07K16/00 ,  C07K16/28 ,  C07K16/40 ,  C12N9/64 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K9/0019 ,  A61P31/16 ,  C07K16/1018 ,  C07K16/28 ,  C07K16/283 ,  C12N9/6424 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30

Abstract: The present invention includes an antibody or antigen-binding fragment thereof that binds specifically to TMPRSS2 and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., influenza virus infections).

公开(公告)号：US12065488B2

公开(公告)日：2024-08-20

申请号：US17516082

申请日：2021-11-01

Applicant: Janssen Biotech, Inc. ,  Applied Molecular Evolution, Inc.

Inventor： Yan Chen ,  Debra Gardner ,  David M. Knight ,  Michael W. Lark ,  Bailin Liang ,  David M. Marquis ,  David J. Shealy ,  Eric Michael Smith ,  Xiao-yu R. Song ,  Vedrana Stojanovic-Susulic ,  Raymond Sweet ,  Susan Tam ,  Alain P. Vasserot ,  Sheng-Jiun Wu ,  Jing Yang

IPC: C07K16/24 ,  A61K39/00

CPC classification number: C07K16/248 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

Abstract: Anti-IL-6 antibodies and antirheumatics are useful to treat and suppress IL-6 related conditions, such as rheumatoid arthritis.

公开(公告)号：US20240270864A1

公开(公告)日：2024-08-15

申请号：US18633795

申请日：2024-04-12

Applicant: Elektrofi, Inc.

Inventor： Paul Brown ,  Daniel Benjamin Dadon ,  James W. Ivey ,  Moin Khwaja ,  Lisa Liu ,  Jeremy Schieferstein ,  Sadiqua Shadbar

IPC: C07K16/28 ,  A61K9/00 ,  A61K39/00 ,  A61K47/14 ,  A61K47/18 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/44 ,  C07K16/06 ,  C07K16/32

CPC classification number: C07K16/2887 ,  A61K9/0019 ,  A61K47/14 ,  A61K47/183 ,  A61K47/20 ,  A61K47/22 ,  A61K47/26 ,  A61K47/44 ,  C07K16/06 ,  C07K16/32 ,  A61K2039/505 ,  A61K2039/54

Abstract: The present disclosure provides high concentration injectable particle suspensions of therapeutic biologics that permit administration without the need for resuspension. In particular, the compositions disclosed herein are highly concentrated low volume injectable particle suspensions that do not require manual premixing or resuspension prior to administration.

公开(公告)号：US20240269268A1

公开(公告)日：2024-08-15

申请号：US18569589

申请日：2022-06-17

Applicant: Elixirgen Therapeutics, Inc.

Inventor： Minoru S.H. KO

IPC: A61K39/295 ,  A61K39/00 ,  A61K39/145 ,  A61K39/215 ,  A61P31/14 ,  C12N15/86

CPC classification number: A61K39/295 ,  A61K39/145 ,  A61K39/215 ,  A61P31/14 ,  C12N15/86 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55583 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70 ,  C07K2319/02 ,  C12N2760/14122 ,  C12N2760/14134 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16222 ,  C12N2760/16234 ,  C12N2770/36122 ,  C12N2770/36143

Abstract: The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding a coronavirus nucleocapsid protein or an influenza virus nucleocapsid protein in operable combination with a mammalian signal peptide. The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding other viral nucleocapsid protein(s) in operable combination with a mammalian signal peptide. The RNA constructs are suitable for active immunization against a virus in a mammalian subject, such as a human subject.

公开(公告)号：US20240269064A1

公开(公告)日：2024-08-15

申请号：US18627994

申请日：2024-04-05

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Jennifer Eng-Wong ,  Whitney Kirschbrown ,  Tarik Ali Khan ,  Jasper Lin ,  Sreedhara Alavattam ,  Amit Garg ,  Sarah Heeson ,  Tanja Badovinac-Crnjevic ,  Christine Wurth

IPC: A61K9/00 ,  A61K9/08 ,  A61K38/47 ,  A61K39/00 ,  A61K39/395 ,  A61K47/18 ,  A61K47/20 ,  A61K47/26 ,  A61P35/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/32

CPC classification number: A61K9/0019 ,  A61K9/08 ,  A61K38/47 ,  A61K39/001106 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/26 ,  A61P35/00 ,  C07K16/32 ,  C12Y302/01035 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/585 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/90

Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

公开(公告)号：US12060430B2

公开(公告)日：2024-08-13

申请号：US17332578

申请日：2021-05-27

Applicant: AMGEN INC.

Inventor： Junming Yie ,  Donghui Shi ,  David J. Lloyd ,  Jinghong Wang ,  Glenn N. Sivits, Jr. ,  Murielle M. Veniant-Ellison ,  Renee Komorowski ,  Neeraj Agrawal ,  Darren L. Bates ,  Brandon C. P. Clavette ,  Ian N. Foltz ,  Shu-yin Ho ,  Christopher Murawsky ,  Xiaoshan Min ,  Zhulun Wang

IPC: A61K39/395 ,  A61K9/00 ,  A61K38/17 ,  A61K38/26 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K38/1703 ,  A61K38/26 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  A61K39/3955 ,  A61K2300/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20240261392A1

公开(公告)日：2024-08-08

申请号：US18568769

申请日：2022-07-08

Applicant: Atossa Therapeutics, Inc.

Inventor： Steven C. QUAY

IPC: A61K39/215 ,  A61K39/00 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  C12N7/00 ,  C12N15/86

CPC classification number: A61K39/215 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/26 ,  A61K47/40 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55572 ,  C12N2750/14143 ,  C12N2770/20034 ,  C12N2770/20043

Abstract: A composition for increasing an immune response to a coronavirus may contain a coronavirus ORF8 protein, an immunogenic fragment of a coronavirus ORF8 protein, a nucleic acid encoding a coronavirus ORF8 protein, or immunogenic fragment of a coronavirus ORF8 protein. A method for increasing an immune response to a coronavirus may involve administering a composition containing a coronavirus ORF8 protein, an immunogenic fragment of a coronavirus ORF8 protein, a nucleic acid encoding a coronavirus ORF8 protein, or immunogenic fragment of a coronavirus ORF8 protein to a subject. Administration of an ORF8 composition may induce an immune response to the ORF8 protein or immunogenic fragment in the subject and may enhance the immune response of the subject to subsequent a coronavirus infection.

公开(公告)号：US20240252627A1

公开(公告)日：2024-08-01

申请号：US18629427

申请日：2024-04-08

Applicant: Longeveron Inc.

Inventor： Joshua M. HARE ,  Ana Marie LANDIN

IPC: A61K39/39 ,  A61K35/28 ,  A61K38/00 ,  A61K39/00 ,  A61K39/145 ,  A61P31/16

CPC classification number: A61K39/39 ,  A61K35/28 ,  A61K39/145 ,  A61P31/16 ,  A61K38/00 ,  A61K2039/515 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/555 ,  A61K2039/55588 ,  A61K2039/70

Abstract: The present invention provides a method of enhancing an immune response to a vaccine by administering a vaccine and a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vaccine in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container.